Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults

NCT01416571 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

78

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza

Interventions

BIOLOGICAL: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted

Sponsor

GlaxoSmithKline